Get informed when a big investor buys or sells
+ FollowNovember 5, 2026 - AI Summary
Overvalued by 24.9% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $4.28 Billion |
|---|---|
| Enterprise Value | $152.95 Million |
| Earnings per Share | $12.42 |
| Beta | 0.52 |
| Outstanding Shares | 59,509,184 |
| P/E Ratio | 58.66 |
|---|---|
| PEG | 146.1 |
| Price to Sales | 1.8 |
| Price to Book Ratio | 0.87 |
| Enterprise Value to Revenue | 0.06 |
| Enterprise Value to EBIT | 0.16 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 1.49 |
| Debt to Equity | 0.05 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, whic...